BRPI0413882A - forma de dosagem farmacêutica sólida - Google Patents

forma de dosagem farmacêutica sólida

Info

Publication number
BRPI0413882A
BRPI0413882A BRPI0413882-1A BRPI0413882A BRPI0413882A BR PI0413882 A BRPI0413882 A BR PI0413882A BR PI0413882 A BRPI0413882 A BR PI0413882A BR PI0413882 A BRPI0413882 A BR PI0413882A
Authority
BR
Brazil
Prior art keywords
dosage form
pharmaceutical dosage
solid pharmaceutical
pharmaceutically acceptable
water soluble
Prior art date
Application number
BRPI0413882-1A
Other languages
English (en)
Inventor
J Erg Rosenberg
Ulrich Reinhold
Bernd Liepold
Gunther Derndl
J Rg Breitenbach
Laman Alani
Soumojeet Ghosh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority claimed from PCT/US2004/027401 external-priority patent/WO2005039551A2/en
Publication of BRPI0413882A publication Critical patent/BRPI0413882A/pt

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMA DE DOSAGEM FARMACêUTICA SóLIDA". Apresenta-se uma forma de dosagem farmacêutica sólida que proporciona melhor biodisponibilidade oral para inibidores de protease de HIV. Em particular, a forma de dosagem compreende uma dispersão sólida de pelo menos um inibidor de protease de HIV e pelo menos um polímero solúvel em água farmaceuticamente aceitável e pelo menos um surfatante farmaceuticamente aceitável, o dito polímero solúvel em água farmaceuticamente aceitável possuindo uma Tg de pelo menos cerca de 50<198>C. De preferência, o surfatante farmaceuticamente aceitável tem um valor de HLB de cerca de 4 a cerca de 10.
BRPI0413882-1A 2003-08-28 2004-08-23 forma de dosagem farmacêutica sólida BRPI0413882A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50617803A 2003-08-28 2003-08-28
PCT/US2004/027401 WO2005039551A2 (en) 2003-08-28 2004-08-23 Solid pharmaceutical dosage form comprising an hiv protease inhibitor solid dispersion

Publications (1)

Publication Number Publication Date
BRPI0413882A true BRPI0413882A (pt) 2006-10-24

Family

ID=37137320

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413882-1A BRPI0413882A (pt) 2003-08-28 2004-08-23 forma de dosagem farmacêutica sólida

Country Status (1)

Country Link
BR (1) BRPI0413882A (pt)

Similar Documents

Publication Publication Date Title
MX358033B (es) Forma de dosificación farmacéutica sólida que comprende al menos un inhibidor de proteasa de hiv.
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
BR0307524A (pt) Composição farmacêutica para inibidores de protease viral de hepatite c
CY1109523T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα παραγωγο βενζοδιαζεπινης και εναν αναστολεα της πρωτεϊνης συντηξης rsv
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2009071219A3 (en) Oral dispersable tablet
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
WO2004071374A3 (en) Once a day orally administered pharmaceutical compositions
BRPI0619868A8 (pt) Dispersão sólida compreendendo um ingrediente ativo tendo um ponto de fusão baixo e comprimido para administração oral compreendendo o mesmo
MY129450A (en) Pharmaceutical composition
ATE516016T1 (de) Selbstemulgierende formulierungen von cetp- hemmern
AR038858A1 (es) Combinacion
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
GB0206200D0 (en) Pharmaceutical compositions
DE60121142D1 (de) Zusammensetzung die paracetamol und niflumic säure enthält
GEP20135819B (en) 3-(2,2,2-trimethylhydrazinium) propionate dihydrate composition of local administration
AR054843A1 (es) Inhibidores de la jnk para el tratamiento de la endometriosis

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 9/14, 9/20, 31/425; A61P 31/14

Ipc: A61K 9/14 (2011.01), A61K 9/20 (2011.01), A61K 31/

B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ABBVIE INC. (US)

B15W Others matters related to applications: legal action concerning application

Free format text: INPI-52400.115597/2014-91 ORIGEM: JUIZO DA 031A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0126330-82.2014.4.02.5101 ACAO ORDINARIA COM PEDIDO DE TUTELA ANTECIPADA AUTOR: ABBVIE INC REU: AGENCIA NACIONAL DE VIGILANCIA SANITARIA - ANVISA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM OS ARTIGOS 8O E 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B10A Cessation: cessation confirmed